Refractory IBD: Medical management

Netherlands Journal of Medicine

Volumn 50, Issue 2, 1997, Pages

  Tremaine, W J ^a  

^a MAYO CLINIC   (United States)

Author keywords

6 Mercaptopurine; Azathioprine; Crohn's disease; Cyclosporine; Inflammatory bowel disease; Methotrexate; Refractory disease; Therapy; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 10; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; ENTERITIS; HUMAN; ULCERATIVE COLITIS;

AZATHIOPRINE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; METHOTREXATE;

EID: 0031057354     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(96)00065-4     Document Type: Conference Paper

References (12)

1. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:641-649.
2. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-987.
3. Sandborn WJ, Van Os EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995;109:1808-1817.
4. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992;305:20-22.
5. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-297.
6. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-1845.
7. Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease [see comments]. N Engl J Med 1989;321:845-850.
8. Jewell DP, Lennard-Jones JE. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 1994;6:499-505.
9. Feagan BG, McDonald JWD, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994;330:1846-1851.
10. Stange EF, Modigliani R, Pena AS, et al. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. Gastroenterology 1995;109:774-782.
11. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflammatory Bowel Disease 1995;1:48-63.
12. Van Dullemen HM, Van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-135.